← Leaderboards
Joseph T. Opferman
St. Jude Children'S Research Hospital
$6,361,955
Attributed
$6,361,955
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $853.6K · FY2010–22$1M$750K$500K$250K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$6,361,955 · 4
By mechanism
R01$5,906,955 · 3
R56$455,000 · 1
Top collaborators
No co-investigators on record.
Most similar at St. Jude Children'S Research Hospital
Same institution · by research overlap
- Ashok A Deniz$12,306,330
- Aditya Shirish Barve$218,266
- Sushree S Sahoo$180,000
- Madeline Niederkorn$435,684
- Dirk Loeffler$1,546,514
Others in their field
Top investigators on “Apoptosis”
- David Heimbrook · Leidos Biomedical Research, Inc.$49,205,802
- Jay A Nelson · Oregon Health & Science University$45,942,124
- John C Reed · University Of Texas Md Anderson Can Ctr$34,437,189
- John A Tainer · Scripps Research Institute$30,637,655
- Henry Shelton Earp · Univ Of North Carolina Chapel Hill$28,872,594
- John D Minna · University Of Texas Sw Med Ctr/Dallas$27,317,167
Research focus
ApoptosisApoptoticUnited States National Institutes Of HealthPreventPositioning AttributeInnovationCell DeathFamily MemberCessation Of LifeHematopoiesisLaboratoriesSeminalIn VivoOuter Mitochondrial MembraneProductionBiologyLeadMitochondriaCellsBcl2 GeneCell SurvivalExhibitsBlood CellsLymphocyte
Grant awards (15)
Mitochondrial matrix-localized MCL-1 regulates hematopoietic stem cell self-renewal and regeneration$455,000
R56 · FY2022 · HL · contact PI
Pathway Specific Combinational Therapy in Poor Prognosis B-Lineage Acute Lymphoblastic Leukemia$410,606
R01 · FY2020 · CA · contact PI
Pathway Specific Combinational Therapy in Poor Prognosis B-Lineage Acute Lymphoblastic Leukemia$398,287
R01 · FY2019 · CA · contact PI
Regulation of Cardiac Death and Energy Metabolism by MCL-1$442,126
R01 · FY2018 · HL · contact PI
Pathway Specific Combinational Therapy in Poor Prognosis B-Lineage Acute Lymphoblastic Leukemia$410,606
R01 · FY2018 · CA · contact PI
Regulation of Cardiac Death and Energy Metabolism by MCL-1$442,948
R01 · FY2017 · HL · contact PI
Pathway Specific Combinational Therapy in Poor Prognosis B-Lineage Acute Lymphoblastic Leukemia$410,606
R01 · FY2017 · CA · contact PI
Regulation of Cardiac Death and Energy Metabolism by MCL-1$442,729
R01 · FY2016 · HL · contact PI
Pathway Specific Combinational Therapy in Poor Prognosis B-Lineage Acute Lymphoblastic Leukemia$410,606
R01 · FY2016 · CA · contact PI
Regulation of Cardiac Death and Energy Metabolism by MCL-1$479,315
R01 · FY2015 · HL · contact PI
Regulation of Cell Death and Mitochondrial Physiology by Anti-Apoptotic MCL-1$407,484
R01 · FY2014 · HL · contact PI
Regulation of Cell Death and Mitochondrial Physiology by Anti-Apoptotic MCL-1$395,842
R01 · FY2013 · HL · contact PI
Regulation of Cell Death and Mitochondrial Physiology by Anti-Apoptotic MCL-1$415,800
R01 · FY2012 · HL · contact PI
Regulation of Cell Death and Mitochondrial Physiology by Anti-Apoptotic MCL-1$420,000
R01 · FY2011 · HL · contact PI
Regulation of Cell Death and Mitochondrial Physiology by Anti-Apoptotic MCL-1$420,000
R01 · FY2010 · HL · contact PI